InMed Provides An Update On Phase 2 Clinical Trial Investigating Cannabinol Cream For Epidermolysis Bullosa
InMed Pharmaceuticals Inc. (NASDAQ: INM) provided an update on its phase 2 clinical trial using investigational drug INM-755 cannabinol (“CBN”) cream for the treatment
